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.t.bstract The possible involvement of phospholipase C~ 
~PLCO) in a crosstalk mechanism between G-protein coupled 
receptors and receptor tyrosine kinases was investigated in 
HeLa-S3 and A-431 cells. A basic activity of the receptor for 
epidermal growth factor (EGF) in the absence of its ligand was 
found only in A-431 cells overexpressing this receptor. Inhibition 
of PLC drastically increased EGF receptor activity in both cell 
lines, suggesting that PLC activity is necessary for the silencing 
of the EGF receptor in the absence of its ligand. Activation of 
PLCI~ and protein kinase C (PKC) via G-protein-linked ATP 
receptors greatly diminished the basic EGF receptor activity in 
~.-431 cells. This negative regulation was prevented by the protein 
tyrosine phosphatase inhibitor, vanadate. The results suggest a 
crosstalk between a G-protein-linked receptor and a receptor 
tyrosine kinase, involving signalling via PLC~ and PKC to a 
downstream protein tyrosine phosphatase functioning in the con- 
trol of EGF receptor activity. 
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I. Introduction 
Signal transduction is the biological language used for cell- 
cell communication i a multicellular organism [1,2]. Because 
target cells are usually addressed by multiple signalling mole- 
cules simultaneously, there is a need for signal sorting and 
integration within the cell. Different signalling pathways hould 
be able to communicate with each other, a phenomenon termed 
receptor crosstalk or transmodulation [3,4]. Understanding the 
mechanisms by which diverse signalling cascades interact with 
each other is fundamental to an understanding of how the 
process of signal transduction is regulated in vivo. 
Transmodulation of signalling pathways has been studied 
with growth factor receptors that possess intrinsic tyrosine ki- 
nase activity (RTKs), e.g. the receptors for epidermal growth 
factor (EGF) and platelet-derived growth factor (PDGF). 
Binding of PDGF to its receptor leads to the phosphorylation 
of the EGF receptor on threonine 654 [3,4]. This phosphoryla- 
tion converts high affinity to low affinity EGF receptors. The 
effect of PDGF is similar, but not identical to the one produced 
by activation of PKC with phorbol esters. In HeLa cells, PDGF 
acts as a dominant inhibitor of signalling via high affinity EGF 
receptors [5]. Mitogen activated protein kinase (MAP) has also 
been shown to negatively regulate the EGF receptor by phos- 
phorylating threonine-669 [6]. Recently, it was suggested that 
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threonine phosphorylation f the EGF receptor is not sufficient 
for negative regulation of its kinase activity, but that protein 
tyrosine phosphatases (PTP) activated by PKC and MAP ki- 
nase may be involved [7,8]. 
Activation of PKC and subsequent transmodulation f the 
EGF receptor requires diacylglycerol (DAG) and calcium ions. 
Production of these activators of PKC is facilitated by 
phosphatidylinositol specific phospholipases C [9]. Two major 
pathways lead to the activation of phospholipase C (PLC) 
[9,10]: one is the receptor tyrosine kinase (RTK) pathway, ex- 
emplified by the PDGF receptor. Activation of the PDGF 
receptor causes dimerization and autophosphorylation on tyro- 
sine residues. The tyrosine phosphorylated residues - in their 
specific amino acid sequence surroundings - represent high 
affinity binding sites for SH2-domain containing proteins (src 
homology domain 2), such as PLCT, Src kinase, and PI3 kinase 
[11]. After binding to the receptor, PLC2/ becomes tyrosine 
phosphorylated and activated. PLC7 then cleaves the lipid pre- 
cursor phosphatidylinositol 4,5-bisphosphate o give both 
DAG and inositol-trisphosphate (IP3). IP3 causes mobilization 
of intracellular calcium, which together with DAG leads to the 
activation of PKC. The second pathway is initiated by the 
activation of G-protein-coupled 'serpentine' receptors, having 
7 transmembrane domains [9,10]. Binding of a ligand to these 
receptors causes dissociation of the heterotrimeric G-protein 
and subsequent activation of PLC]~ by the G a subunit. PLCfl 
catalyses the same reaction as PLC~'. The common theme in 
both of these signalling pathways appears to be activation of 
PKC through the action of PLC species. We therefore investi- 
gated whether G-protein-activated PLCfl is involved in the 
transmodulation f RTK activity. It is shown here that PLCfl 
activity is necessary to silence the EGF receptor in the absence 
of the ligand. This inactivation probably involves a protein 
tyrosine phosphatase that is coupled to G-protein-linked recep- 
tors via PLC~ and PKC. 
2. Materials and methods 
The human cell lines HeLa-S3 and A-431 were obtained from the 
American Type Culture Collection. Minimum Essential Medium 
(MEM) was from BioWhittaker. Horse serum was from Boehringer- 
Mannheim. Epidermal growth factor and the PLC inhibitor substance 
U73122 were from Biomol; tetraacetate-phorbol-13-myristate 
(TPA = PMA) and adenosine triphosphate (ATP) were from Sigma. 
HeLa cells and A-431 cells were routinely grown in MEM/10% horse 
serum. For experiments, they were seeded into 24-well culture vessels 
(2-3 x 104 per well) and cultured for 3-4 days. The medium was then 
replaced with fresh medium supplemented with 0.5% horse serum. 
After additional 24 h, ceils were treated for 5 rain with EGF (final 
concentration 1or 50 nM) dissolved in PBS, with TPA dissolved in 
DMSO (final concentration 2/IM), or with ATP dissolved in PBS and 
neutralized to pH 7.0 (final concentration 150/IM). Sodium vanadate 
(final concentration 100 ¢tM) was added one hour before the respective 
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factors. PLC was inhibited by the addition of U73122 dissolved in 
DMSO (final concentration 30/IM) for 40 min. As a control, cells were 
treated with either PBS and/or with DMSO. The medium was aspirated 
and ceils were lysed in 150/zl of electrophoresis ample buffer. Samples 
were applied to 7% SDS-PAGE. Immunoblotting was performed using 
an anti-phosphotyrosine antibody (PY-20) conjugated with horseradish 
peroxidase (ICN), followed by enhanced chemiluminescence detection 
(ECL from Amersham). 
3. Results 
The intrinsic tyrosine kinase activity of the EGF receptor 
is activated upon ligand binding and is responsible for the 
autophosphorylation of the receptor and the subsequent phos- 
phorylation of substrate proteins on tyrosine residues. Im- 
munoblotting of cell lysates with anti-phosphotyrosine anti- 
bodies was used to assess this activity. 
Phosphorylation of the EGF receptor on tyrosine residues 
was not detectable in HeLa cells that were serum-starved for 
24 h, e.g. in the absence of EGF, After treatment with the 
phospholipase C inhibitor U73122, a tyrosine phosphorylated 
protein of Mr 160 kDa was observable (Fig. 1), corresponding 
to the autophosphorylated EGF receptor as verified by im- 
munoprecipitation with an anti-EGF receptor antibody (not 
shown). 
Human squamous carcinoma cells A-431 overexpress the 
EGF receptor. Serum-starvation for24 h greatly diminished the 
amount of autophosphorylated EGF receptors (Fig. 1). How- 
ever, a basic amount of tyrosine phosphorylation was still de- 
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Fig. 1. Tyrosine phosphorylated proteins in HeLa cells and A-431 cells 
after treatment with PLC inhibitor. Cells were serum-starved for 24 h. 
The PLC inhibitor U73122 (dissolved in DMSO) was added for 40 rain 
and EGF (50 nM) for 5 min. Control cells were treated with DMSO. 
Cells were lysed and tyrosine phosphorylated proteins were detected by 
immunoblotting using anti-phosphotyrosine a tibodies (PY-20) conju- 
gated with horseradish peroxidase, and subsequent ECL development. 
The position of the EGF receptor is indicated as EGF-R. 
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Fig. 2. Downregulation of EGF receptor activity in A-431 cells treated 
with ATP and TPA. Serum-starved cells were incubated with DMSO 
or with the PLC inhibitor U73122 in DMSO for 40 rain followed by 
stimulation with ATP and TPA for 5 rnin. Control cells received DMSO 
alone. Cells were lysed and tyrosine phosphorylated proteins were de- 
tected as described in legend to Fig. 1. The position of the EGF receptor 
is indicated as EGF-R. 
tectable. As in HeLa cells, inhibition of PLC caused increased 
tyrosine phosphorylation of the EGF receptor in A-431 cells 
(Fig. 1). Stimulation of A-431 cells with EGF caused strong 
phosphorylation f the 160 kDa protein, corroborating its iden- 
tity as the EGF receptor. In addition, tyrosine phosphorylation 
of other cellular proteins was also visible. The pattern of tyro- 
sine phosphorylated cellular proteins after EGF treatment was 
not identical but quite similar to the one observed after inhibi- 
tion of PLC. These data indicate that inhibition of PLC causes 
activation of the EGF receptor tyrosine kinase in the absence 
of its ligand. 
If inhibition of PLC increased EGF receptor activity, then 
activation of PLC should have the opposite ffect. The presence 
of a basic EGF receptor activity in serum-starved A-431 cells 
permits one to investigate the effect of PLC activators on EGF 
receptor autophosphorylation. PLCfl species are activated by 
G-protein-coupled seven transmembrane domain ('serpentine') 
receptors [9,10]. Extracellular ATP is an agonist of G-protein- 
linked P2-purinergic receptors in A-431 cells [12]. It is shown 
in Fig. 2 that ATP treatment greatly diminished the amount of 
tyrosine phosphorylated EGF receptors in serum-starved cells, 
corroborating that activation of PLCfl leads to an inactivation 
of the EGF receptor tyrosine kinase. This inactivation was 
prevented in cells that were pretreated with PLC inhibitor 
(Fig. 2), confirming that transmodulation f the EGF receptor 
after ATP treatment occurred via activation of PLCfl species. 
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:ig. 3. Requirement ofprotein tyrosine phosphatase activity for silenc- 
ng of the EGF receptor (EGF-R). Serum-starved cells were incubated 
vith PBS (-vanadate) or with sodium vanadate dissolved in PBS 
+vanadate) for 1 h, followed by stimulation with ATP or TPA for 5 
nin. Control cells received DMSO (control 1) or PBS (control 2). Cells 
vere lysed and tyrosine phosphorylated proteins were detected as de- 
,cribed in legend to Fig. 1. 
PLC liberates diacylglycerol (DAG) from its membrane lipid 
precursor. DAG is an activator of PKC. In cultured cells, this 
kinase can also be activated by the structurally related phorbol 
ester, TPA. It is shown in Fig. 2 that treatment of A-431 cells 
with TPA decreased autophosphorylation of the EGF receptor. 
Fhis inactivation was not prevented by the PLC inhibitor. 
It was suggested recently that inhibition of the ligand-in- 
duced signalling by the EGF receptor may involve a protein 
tyrosine phosphatase (PTP) downstream of PKC [7]. Serum- 
starved A-431 cells were therefore preincubated with the PTP 
inhibitor, vanadate, followed by stimulation with ATP and 
TPA. This experiment revealed that silencing of the EGF recep- 
tor after treatment with ATP and TPA does not occur when 
tyrosine phosphatases are inhibited (Figs. 3,4). 
Activation of PKC by TPA or PDGF has been shown to 
cause inhibition of the ligand induced signalling by the EGF 
receptor [3]. A-431 cells were therefore treated with EGF and 
ATP simultaneously. Tyrosine phosphorylation of the EGF 
receptor increased rapidly after addition of EGF alone, and 
reached a maximal level after 20 min. In the presence of ATE 
however, EGF-induced autophosphorylation was markedly re- 
duced, suggesting that activation of PLCfl by G-protein-cou- 
pled ATP receptors is inhibitory for signalling by the EGF 
receptor also in the presence of the ligand, EGF. 
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Fig. 4. Inhibition of EGF-induced autophosphorylation of the EGF 
receptor (EGF-R) in the presence of ATP. Serum-starved A-431 cells 
were stimulated with EGF (1 nM) alone ore with EGF and ATP (150 
pM) simultaneously. At the indicated times after stimulation, cells were 
lysed and tyrosine phosphorylated proteins were detected as described 
in legend to Fig. 1. The basic level of EGF receptor phosphorylation 
before stimulation is not visible in this case because of the short expo- 
sure time during ECL development. 
4. Discussion 
Growth factor receptors with intrinsic tyrosine kinase activ- 
ity are considered to enter an inactive state in the absence of 
the ligand. Binding of the ligand induces dimerization and 
autophosphorylation of the receptors on tyrosine residues [11], 
followed by tyrosine phosphorylation of substrate proteins. 
Protein tyrosine phosphatases counteract the kinases and re- 
move phosphate from signalling molecules [13]. Here we 
showed that the EGF receptor is active and produces a signal 
even in the absence of EGF when PLC species are inhibited. 
This suggests that deprivation of the ligand by serum-starvation 
is not sufficient o retain the EGF receptor in an inactive state. 
Instead, a basic activity of PLC species and, hence, a continu- 
ous inhibitory signalling cascade is responsible and necessary 
for a complete silencing of the EGF receptor in the absence of 
the ligand. 
In serum-starved A-431 cells, the basic PLC activity appar- 
ently is not sufficient o inactivate all EGF receptors. This is 
easily explained by the presence of large amounts of receptors 
due to an overexpression f the respective gene [14]. However, 
after ATP treatment and subsequent activation of PLCfl, the 
residual EGF receptor activity was greatly diminished. This 
suggests that not only PLCy, but also PLCfl is involved in the 
transmodulation of signalling pathways and in the heterolo- 
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Fig. 5. Proteins involved in the transmodulation f the EGF receptor 
by other receptor tyrosine kinases and G-protein-linked receptors. 
Upon binding of the ligand, G-protein coupled 'serpentine' receptors 
activate PLC gamma, and RTKs (PDGF receptor) PLC]~. Both of these 
pathways increase the diacylglycerol (DAG) and calcium ion concen- 
tration, resulting in activation of protein kinase C (PKC). PKC activa- 
tion results in the phosphorylation f the EGF receptor at threonine 
residues, converting high affinity to low affinity receptors. Concomi- 
tantly, a protein tyrosine phosphatase (PTP) is activated ownstream 
of PKC, which dephosphorylates yrosine residues on the EGF recep- 
tor. 
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gous regulation of RTK activity. Apparently, activation of 
G-protein-coupled 'serpentine' receptors such as P2 purinergic 
ATP receptors produces a signal that influences EGF receptor 
activity, suggesting a crosstalk between signalling cascades of 
G-protein-linked receptors and RTK-mediated signalling. 
Activation of PLCfl after binding of extracellular ATP to P2y 
or P2u receptors is well documented [12]. In accordance with 
this, inhibitors of PLC prevented silencing of the EGF receptor 
by ATP treatment. However, inactivation of the EGF receptor 
was achieved with TPA even in the presence of PLC inhibitor. 
This suggests that ATP exerts its effect on the EGF receptor 
via PLCfl-produced DAG and subsequent activation of PKC. 
Dephosphorylation f the EGF receptor after ATP and TPA 
treatment was sensitive to the protein tyrosine phosphatase 
inhibitor, vanadate, suggesting that the activity of such a phos- 
phatase is required for silencing of the EGF receptor in the 
absence of a ligand, and that this PTP lies downstream of PKC. 
Transmodulation of the EGF receptor after PDGF treat- 
ment has been assessed by determining the conversion of high 
affinity to low affinity EGF binding sites, resulting from activa- 
tion of the PLCy/PKC pathway and threonine phosphorylation 
of the EGF receptor [3,4]. This transmodulation therefore 
should not be sensitive to the PTP inhibitor, vanadate. Here we 
showed that activation of PKC with phorbolester does not 
decrease autophosphorylation of the EGF receptor when PTPs 
are inhibited, suggesting that threonine phosphorylation is not 
responsible for inhibition of the EGF receptor activity. Instead, 
silencing of the EGF receptor in the absence of the ligand 
requires permanent activation of a protein tyrosine phospha- 
tase via the PLC/PKC pathway. 
Interestingly, activation of PLC has been shown for all of the 
known ligands of G-protein-coupled receptors, including those 
for bombesine [15], vasopressin [16], angiotensin, histamine, 
acetylcholine, thromboxane A2, bradykinin [9], ATP [12], and 
thrombin [17]. In addition, some of these ligands, including 
ATE have been shown to convert high affinity to low affinity 
EGF receptors, involving a PKC dependent mechanism 
[15,16,18]. Therefore, activation of PKC and transmodulation 
of the EGF receptor by phosphorylation threonine residues, 
as well as the subsequent activation of an EGF receptor specific 
protein tyrosine phosphatase, are likely to represent compo- 
nents of a crosstalk mechanism common to all of these ligands 
of G-protein-coupled receptors and also to those RTKs that 
activate PLCy (Fig. 5). 
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